NASDAQ:DMAA
Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. reported net income of $5.9M in fiscal 2025.Summary generated from Drugs Made In America Acquisition Corp.'s SEC filings. Latest annual report filed Apr 15, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count changen/a
Financials
| Item | 2025 |
|---|---|
| Revenue | n/a |
| Operating income | −3 |
| Net income | 6 |
| Free cash flow | n/a |
Recent filings
- 8-KEntry into a material agreement
Sep 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KEntry into a material agreement
Jul 20, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026 - 8-KEntry into a material agreement
May 5, 2026 - 8-KAmendment to articles or bylaws
May 1, 2026 - 8-KEntry into a material agreement
Apr 28, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Apr 15, 2026